NASDAQ · Biotechnology

DRTS (DRTS) Stock

$11.59 -5.08% NASDAQ: DRTS Healthcare

Valuation

MetricValue
Price$11.59
Market Cap$1.05B
P/E Ratio-18.73
P/B Ratio12.54
P/S Ratio0.00
EPS (TTM)$-0.43
52-Week High$13.64
52-Week Low$2.85
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-90.51%
ROA-30.50%
ROCE-53.85%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.21
Current Ratio7.09

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-14.0M$-32.0M$36.0M$-36.0M$-42.0M
Net Profit$-27.0M$-34.0M$-29.0M$-32.0M$-43.0M
EPS$-0.67$-0.53$-0.42$-0.45$-0.53
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$42.0M$120.0M$107.0M$86.0M$107.0M
Total Liabilities$77.0M$14.0M$23.0M$24.0M$29.0M
Cash$23.0M$6.0M$13.0M$14.0M$16.0M
Borrowings$54.0M$5.0M$13.0M$13.0M$14.0M

Latest News

Alpha Tau Medical Treats First Immunocompromised Patient in Alpha DaRT Study MT Newswires · Jul 15, 2026 Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center GlobeNewswire · Jul 15, 2026 New Strong Sell Stocks for July 7th Zacks · Jul 7, 2026 New Strong Sell Stocks for July 2nd Zacks · Jul 2, 2026 Alpha Tau Medical’s (DRTS) First International Brain Cancer Use Tests The Breadth Of Its Alpha DaRT Platform Simply Wall St. · Jun 27, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-12.0M$-24.0M$-18.0M$-20.0M$-27.0M
Investing Cash Flow$16.0M$-91.0M$12.0M$19.0M$-27.0M
Financing Cash Flow$0$94.0M$5.0M$0$0
Net Cash Flow$8.0M$-17.0M$9.0M$1.0M$-1.0M
Free Cash Flow$-15.0M$-25.0M$-24.0M$-22.0M$-33.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA-18.35
FCF Yield-3.74%
Quick Ratio7.79
Interest Coverage—
Return 1Y339.87%
Return 3Y230.17%
Return 5Y25.92%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACIU $2.31 +0.22% -4.04 $234.59M 0.00%
ALDX $1.60 +3.23% -2.77 $96.51M 0.00%
AMRNAmarin Corporation plc $14.58 +0.80% -9.00 $301.45M 0.00%
ANRO $28.67 +0.70% -6.29 $1.01B 0.00%
CADL $10.59 +0.09% -11.10 $775.93M 0.00%

About DRTS

DRTS is led by CEO Uzi Sofer, employs 125 people, headquartered in IL, publicly traded since 2021.

DRTS stock trades at $11.59 with a market capitalization of $1.05B. The stock is valued at a price-to-earnings (P/E) ratio of -18.73, price-to-book of 12.54, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.85 and $13.64, and currently trades 15.0% below its 52-week high.

On profitability, DRTS generates a return on equity (ROE) of -90.51%, return on capital employed of -53.85%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides